who should take semaglutide for weight loss The Digital Semaglutide Program For

2023;83(19):3485e35013411

Karn, S

Lean mass preservation during a cut: Emerging data favor Tirzepatide when paired with resistance training, adequate protein, and recovery

Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease, and other related cardiometabolic diseases

This is a drug wastage tracking requirement, not a separate payment modifier

Contact your GP for routine assessment if: Urinary frequency significantly disrupts daily activities or sleep You notice persistent changes in urine colour, smell, or appearance Urinary symptoms persist beyond the initial adjustment period (typically 48 weeks) You have concerns about medication side effects or diabetes control Your healthcare provider can perform appropriate investigations, including urinalysis, renal function tests, and HbA1c measurement, to determine the underlying cause of urinary changes and adjust your treatment plan accordingly